White Papers
Governed thinking for high-stakes drug discovery decisions.
OmicsX white papers examine where drug discovery decisions fail, why more information is not enough, and how governed systems can determine what should proceed, pause, stop, or be re-baselined.
featured White Papers
flagship Paper
Decision Operating Systems for Drug Discovery
Why programs need governed progression, not more disconnected intelligence.
This flagship paper explains why high-risk drug development requires governed progression systems and how decision records, evidence boundaries, permission logic, and audit-ready outputs can change what moves forward.
Key Topics
- Why drug programs fail before they are stopped
- The limits of more data and disconnected insights
- Intelligence vs. AI vs. Decision Systems
- What governed progression really means
- How decision records create clarity, control and accountability
White Paper Library
Target & Molecule
Target-to-Asset Decision Governance
Why difficult targets and the molecules against them must earn permission separately.
Request Access
MODALITY & PROGRAM
Modality Programs Should Not Advance by Assumption
Decision Governance for ADC, DAC, Molecular Glue and complex modality development.
Request Access
VENDOR & EXECUTION
Vendor Output is Not Evidence Until It Survives Governance
Execution governance for outsourced drug development programs.
Request Access
AI / DECISION SYSTEMS
AI Finds Possibilities. Decision Systems Govern Progression.
Why AI drug discovery platforms and decision-governance systems solve different problems.
Request Access
Capital & Governance
Funding Allocation Should Be Governed Before Capital Compounds Risk
How evidence-bound decisions improve portfolio and board-level capital discipline.
Request Access
Capital & BD / Sourcing
Why BD-Sourced Molecules Need Decision Governance
A framework for evaluating external molecules before licensing, partnering, or acquisition.
Request Access
Strategy & Risk
Why Most Drug Programs Fail Before They Are Stopped